Open Access

Common 4977 bp deletion and novel alterations in mitochondrial DNA in Vietnamese patients with breast cancer

  • Jan Dimberg1,
  • Thai Trinh Hong2,
  • Linh Tu Thi Nguyen2,
  • Marita Skarstedt3,
  • Sture Löfgren3 and
  • Andreas Matussek4Email author
Contributed equally
SpringerPlus20154:58

https://doi.org/10.1186/s40064-015-0843-8

Received: 3 December 2014

Accepted: 22 January 2015

Published: 3 February 2015

Abstract

Mitochondrial DNA (mtDNA) has been proposed to be involved in carcinogenesis and ageing. The mtDNA 4977 bp deletion is one of the most frequently observed mtDNA mutations in human tissues and may play a role in breast cancer (BC). The aim of this study was to investigate the frequency of mtDNA 4977 bp deletion in BC tissue and its association with clinical factors.

We determined the presence of the 4977 bp common deletion in cancer and normal paired tissue samples from 106 Vietnamese patients with BC by sequencing PCR products.

The mtDNA 4977 bp deletion was significantly more frequent in normal tissue in comparison with paired cancer tissue. Moreover, the incidence of the 4977 bp deletion in BC tissue was significantly higher in patients with estrogen receptor (ER) positive as compared with ER negative BC tissue. Preliminary results showed, in cancerous tissue, a significantly higher incidence of novel deletions in the group of patients with lymph node metastasis in comparison with the patients with no lymph node metastasis.

We have found 4977 bp deletion in mtDNA to be a common event in BC and with special reference to ER positive BC. In addition, the novel deletions were shown to be related to lymph node metastasis. Our finding may provide complementary information in prediction of clinical outcome including metastasis, recurrence and survival of patients with BC.

Keywords

Breast cancerMitochondrial DNA mutationmtDNA deletion

Introduction

The incidence of different cancers have increased both in developed and in developing countries (Jemal et al. 2011). Breast cancer (BC) is one of the most common cancers affecting women worldwide and the incidence is rapidly rising in Asian countries. In Vietnam, the incidence rate is 12 to 27per 100 000 (Anh & Duc 2002; Le et al. 2002) while the incidence for women living in Western countries is about 80 to 100 per 100 000 (Jemal et al. 2011).

The development of BC involves a progression through intermediate states and processes leading to evolution to carcinoma in situ, invasive carcinoma and metastasis. Mutations in nuclear genes such as tumor-suppressor genes and oncogenes, but also environmental exposures contribute to the development of BC (McPherson et al. 2000; Polyak 2007; Schwartz et al. 2008). For example high penetrance genes as BRCA1, BRCA2, PTEN and TP53 are responsible for the hereditary BC syndromes (Polyak 2007; Schwartz et al. 2008).

It is necessary to identify molecular markers to predict the progression, metastasis, recurrence and survival in BC. Hormone receptors status is used for identifying a high-risk phenotype and to select suitable regime for treatment (Banin Hirata et al. 2014). Other tumor markers suggested useful in diagnostic procedures and for prognosis in BC are expression of chemokines, chemokine receptors and growth factors (Banin Hirata et al. 2014).

Alongside the nuclear genome, the human cell contains hundreds to several thousand copies of the 16 569 base pair circular mitochondrial DNA (mtDNA) including 37 genes (Birch-Machin 2006; Penta et al. 2001). Within cells the mtDNA has the capacity to form a mixture of both wild-type and mutant mtDNA genotypes in a state called heteroplasmy (Birch-Machin 2006; Penta et al. 2001).

mtDNA has been proposed to be involved in carcinogenesis and ageing (Birch-Machin 2006; Penta et al. 2001) and somatic mtDNA mutations have been reported in various types of cancer, including BC (Penta et al. 2001; Chen et al. 2011; Eshaghian et al. 2006; Larman et al. 2012; Yadav & Chandra 2013; Ye et al. 2008). The main reason for its involvement in carcinogenesis is probably that mtDNA has a high susceptibility to undergo mutations due to its lack of histones, limited repair mechanisms and a high rate of generation of reactive oxygen species (Birch-Machin 2006; Penta et al. 2001). The mitochondrial 4977 bp deletion, also known as the common deletion, is one of the most frequently observed mtDNA mutations and has been associated with different cancers (Chen et al. 2011; Eshaghian et al. 2006; Ye et al. 2008; Abnet et al. 2004; Dani et al. 2003). The deletion occurs between nucleotides 8470 and 13 447 and spans five tRNA genes and seven genes encoding subunits of cytochrome c oxidase, ATPases and complex I (Chen et al. 2011; Ye et al. 2008). Moreover, the deletion has a 13 bp direct repeat flanking the 5′- and 3′-end breakpoints at nucleotide position (np) 8470/8482 and np 13 447/13 459, respectively (Chen et al. 2011; Ye et al. 2008).

In this study, we determined the frequency of the 4977 bp deletion in BC and corresponding non-cancerous breast tissue samples from 106 Vietnamese patients with BC.

Materials and methods

Patients and tissue specimens

This study comprised of 106 consecutive female patients with BC, from northern Vietnam. Tissue specimens were collected when the patients underwent surgical resections at the National Cancer Hospital, Tam Hiep, Hanoi, Vietnam. The mean age of the patients were 52 years (range 24-89 years). Clinicopathological characteristics from the patients were received from surgical and pathological records. Tumor tissue and adjacent normal tissue (about 5 cm from the tumor) from each patient were excised and immediately frozen at 80°C until further analysis.

Clinical and clinicopathologic classification and staging were determined according to the American Joint Committee on Cancer (AJCC) criteria. The tumors (invasive ductal carcinoma) were classified according to TNM staging system and the distribution was: T1N0M0 (n = 8), T2N0M0 (n = 42), T3N0M0 (n = 5), T1N1M0 (n = 2), T1N2M0 (n = 2), T2N1M0 (n = 28), T2N2M0 (n = 3), T3N1M0 (n = 7), T3N2M0 (n = 1), T4N1M0 (6) and T2N1M1 (n = 2).

Tumor grade of 79 patients was known: well differentiated (n = 6), moderately differentiated (n = 56) and poorly differentiated (n = 17). In 24 cases information regarding positive and negative expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in tumor tissue, was available. ER + (n = 12), PR + (n = 5) and HER2 + (n = 19). The study was approved by the local Ethics Committee at the Vietnam National University, Hanoi, Vietnam (2422/QD-KHCN) and all patients gave their consent to participate in the study.

PCR assay

DNA was isolated from all BCs and paired normal tissues by QIAamp DNA Mini kit (Qiagen, Hilden, Germany). To screen for the mitochondrial 4977 deletion, a nested PCR was developed to detect low levels of the deletion. Two pairs of PCR primers were designed for the first amplicon of 496 bp and the second amplicon of 381 bp (Table 1). For the first amplicon, the primers were designed to be distant enough to detect only mtDNAs containing deletions. To assess the presence of mtDNA and to detect heteroplasmy/homoplasmy regarding 4977 deletion, PCR primers were designed in the region of the genes NADH dehydrogenase 1 (ND1) and ND3 resulting in products of 433 bp and 246 bp, respectively (Table 1).
Table 1

Primer sequences and product sizes for mtDNA 4977 bp deletion analysis in this study

Primer

Primer sequence

Position

Product

Note

mtDNA-forward

5′-GACGCCATAAAACTCTTCAC-3′

3457-3476

433 bp

ND1-region

mtDNA-reverse

5′-GGTTGGTCTCTGCTAGTGTG-3′

3889-3870

  

4977-1forward

5′-TCAATGCTCGAAATCTGTGG-3′

8167-8187

496 bp

First PCR

4977-1reverse

5′-GTTGACCTGTTAGGGTGAGAAG-3′

13639-13618

  

4977-2forward

5′-ACAGTTTCATGCCCATCGTC-3′

8196-8215

381 bp

Second PCR

4977-2reverse

5′-GCGTTTGTGTATGATATGTTTGC-3′

13553-13531

  

10398-forward

5′-CCTGCCACTAATAGTTATGTC-3′

10307-10327

246 bp

ND3-region

10398-reverse

5′-GATATGAGGTGTGAGCGATA-3′

10552-10533

  

Except for the second PCR run for 4977 deletion, DNA was amplified in a total volume of 12.5 μl containing 0.2 μM of each primer (TIB Molbiol, Berlin, Germany), 1.8 mM MgCl2, 200 μM of each deoxynucleotide triphosphate, 0.04 units Taq DNA polymerase and reaction buffer [20 mM Tris-HCl (pH 8.3), 20 mM KCl, 5 mM (NH4)2SO4] (Fermentas, Burlington, Canada). Amplification was done with an initial denaturation at 95°C for 4 min followed by 35 cycles at 92°C for 30 s (denaturation), 54°C for 30 s (annealing), 72°C for 45 s (extension) and final elongation at 72°C for 10 min. For the second PCR run regarding the 4977 deletion, the conditions were the same as above except that an annealing temperature of 60°C and a total number of 32 cycles was used. The amplified PCR products were visualized by UV-illumination on 2% agarose gel containing Gel Red (Biotium, Inc., Hayward, CA). The band reflecting the 4977 common deletion and all the other bands that were obtained at different levels on the gel were purified with Gel Extraction kits (Qiagen, Hilden, Germany), followed by commercial sequencing (GATC Biotech, Köln, Germany).

Statistical analysis

Differences in the rate of mtDNA deletions were analyzed using the Chi-square test. Statistical analyses were performed using SPSS for Windows computer package (IBM SPSS Statistics, 2012, version 19; SPSS Inc., Chicago, IL). Results were considered significant at p < 0.05.

Results

Frequency of mtDNA 4977 bp deletion in patients with BC

All samples showed clear bands with mtDNA and 10398 primers representing 433 bp and 246 bp respectively (Figure 1). In lanes 2, 6 and 9 (Figure 1), three novel deletions were detected (700, 220 and 700 bp, respectively) which were confirmed by sequencing. For the 4977 bp deletion, represented by bands 381 bp, we defined two types of signals by nested PCR: negative and positive clear band (Table 2). The deletion was detected in 68.8% (73/106) of cancerous tissues and 84.0% (89/106) of normal paired tissues (Table 2) (p < 0.01).
Figure 1

Agarose gel showing polymerase chain reaction (PCR) products from four breast cancer tissue/normal paired tissue. Nested PCR (381 bp, lane 2/3, 4/5, 6/7, 8/9); 10398 (246 bp, lane 10/11, 12/13, 14/15, 16/17); mtDNA (433 bp, lane 18/19, 20/21, 22/23, 24/25) and discovered novel deletions (700 bp, lane 2 and 9; 220 bp, lane 6). Lane 1, molecular marker.

Table 2

Mitochondrial DNA 4977-bp deletion in Vietnamese patients with breast cancer

  

Prevalence of deletion (n)

Parameters

No. of cases

Negative

Positive

Cancer tissue

106

33

73

Normal paired tissue

106

17

89

Stage*

T1N0M0

8

2

6

T2N0M0

42

12

30

T3N0M0

5

2

3

T1N1M0

2

1

1

T1N2M0

2

2

0

T2N1M0

28

6

22

T2N2M0

3

2

1

T3N1M0

7

2

5

T3N2M0

1

0

1

T4N1M0

6

3

3

T2N1M1

2

1

1

*Cancer tissue.

With regard to disease stage, the patients were divided into two sub-groups, one with no metastasis to lymph node or other organs (T1-3, N0, M0) and one with spread (T1-4, N1-3, M0-1). However, no significant difference was seen with respect to the frequency of 4977 bp deletion. Nor were tumor grade or age associated with the 4977 bp deletion (data not shown).

We found a significantly (p < 0.01) higher rate of the 4977 bp deletion in patients with ER+, 91.2% (11/12) compared with ER−, 41.2% (5/12). Neither PR nor HER2 showed statistically significant correlation to the presence of 4977 bp deletion.

Detection of novel mtDNA deletions

After nested PCR, we detected different bands in addition to the 381 bp which represents the 4977 bp deletion. The bands that were both larger and smaller than 381 bp were purified, sequenced and the corresponding deletions were analyzed using the program BLASTn (Altschul et al. 1990). The deletions were checked against the MITOMAP database (MITOMAP 2013) and other possible reference sources, with the consequence that we characterize our findings as novel deletions. Tables 3 and 4 summarize the novel deletions in tumor and normal tissue with information about breakpoints, deletion size, repeat location and type, respectively. We found 36 novel deletions in the tumor tissue distributed among 33 patients and 30 novel deletions in the normal tissue spread over 26 patients.
Table 3

Novel mtDNA deletion (n = 36) detected in breast cancer tissue

Patient code

Deletion junction (nt:nt)

Deletion size (bp)

Repeat location (nt)

Repeat type

8

8712:13256

4543

8709-8711/13256-13258

I, 3/3

10

8318:13500

5181

-

NR

11

8249:12960

4710

-

NR

20

8228:13479

5250

8228/13478

D, 1/1

26

8329:13411

5081

8330-8333/13409-13412

I, 4/4

28

8300:13448

5147

-

NR

30

8439:13080

4640

8435-8439/13074-13079

D, 5/6

31

8241:13278

5036

8241/13277

D, 1/1

32

8405:13165

4759

8404-8405/13163-13164

D, 2/2

33

8553:13206

4652

8552-8553/13206-13207

I, 2/2

33

8338:12588

4249

8333-8338/12582-12587

D, 5/6

38

8271:13358

5086

8271/13357

D, 1/1

39

8532:13397

4864

8526-8532/13390-13396

D, 7/7

41

8586:13457

4870

8582-8586/13452-13456

D, 4/5

44

8282:13488

5205

8279-8282/13484-13487

D, 4/4

44

8309:13474

5164

8310-8315/13474-13479

D, 6/6

52

8256:13412

5155

-

NR

53

8436:13528

5091

8430-8436/13520-13527

D, 5/7

55

8223:13415

5191

-

NR

56

8319:13498

5178

8320-8321/13498-13499

I, 2/2

60

8272:12908

4635

8272/12907

D, 1/1

61

8474:13525

5050

8463-8474/13514-13524

D, 10/12

68

8273:13138

4864

-

NR

69

8227:13422

5194

8227-8228/13420-13421

I, 2/2

70

8448:13499

5050

-

NR

73

8216:13473

5256

8216/13472

D, 1/1

76

8262:13415

5152

8260-8262/13412-13414

D, 2/3

77

8354:13411

5056

-

NR

79

8252:13490

5237

-

NR

86

8324:13491

5166

8310-8324/13474-13490

D, 13/17

90

8282:13488

5205

8279-8282/13484-13487

D, 4/4

91

8296:13372

5076

8294-8296/13370-13372

D, 3/3

99

8222:13440

5217

8222/13439

D, 1/1

101

8443:13496

5052

8441-8443/13492-13495

D, 3/4

102

8369:12552

4182

8370-8379/12551-12559

I, 9/10

102

8505:13405

4899

8503-8507/1340-1344

I, 5/5

D, direct repeat; NR, no repeat; nt, nucleotide; I, indirect repeat.

Table 4

Novel mtDNA deletion (n = 30) detected in breast normal tissue

Patient code

Deletion junction (nt:nt)

Deletion size (bp)

Repeat location (nt)

Repeat type

4

8251:13414

5162

8244-8250/13409-13415

D, 7/7

6

8257:13447

5189

8257/13446

D, 1/1

8

8226:13459

5232

8225-8227/13459-13461

D, 3/3

9

8326:13480

5153

8327-8328/13479-13480

D, 2/2

11

8332:13210

4877

-

NR

19

8313:13522

5208

8314-8316/13521-13523

D, 3/3

19

8300:13206

4905

8299-8300/13204-13205

D, 2/2

20

8263:13461

5197

8259-8263/13457-13461

I, 5/5

20

8231:13328

5096

8228-8231/13328-13332

D, 4/5

24

8564:13334

4769

8560-8564/13328-13332

D, 5/5

28

8305:13533

5227

8304-8305/13531-13532

D, 2/2

32

8256:13313

5056

8254-8257/13309-13312

I, 4/4

38

8435:13474

5038

8434-8435/13472-13473

D, 2/2

41

8396:13466

5069

8395-8396/13464-13465

D, 2/2

43

8299:13463

5163

8294-8299/13457-13462

D, 5/6

50

8234:13286

5051

8231-8234/13283-13285

D, 3/4

52

8297:13428

5130

8295-8297/13425-13427

D, 2/3

52

88801:13462

4660

8787-8801/13448-13461

D, 13/15

59

8355:13440

5084

8343-8355/13428-13439

D, 11/13

61

8216:13396

5179

-

NR

65

8425:13297

4871

8421-8425/13291-13296

I, 5/6

67

8362:13465

5102

8363-8364/13465-13466

I, 2/2

79

8492:13529

5036

8491-8492/13527-13528

D, 2/2

79

8215:13117

4901

8214-8215/13115-13116

D, 2/2

88

9160:12966

3805

9149-9160/12954-12965

D, 12/12

92

8556:13170

4613

8553-8556/13166-13169

D, 3/4

101

8349:13421

5071

8348-8349/13419-13420

D, 2/2

103

8312:13467

5154

8313/13466

D, 1/1

106

8259:12994

4734

-

NR

107

8534:13399

4864

8526-8534/13390-13398

D, 8/9

D, direct repeat; NR, no repeat; nt, nucleotide; I, indirect repeat.

A number of patients with at least one novel deletion in the cancerous tissue were 12 with no involved lymph nodes (N0) and in 21 with involved lymph nodes (N1-2). Moreover, we observed, in cancerous tissue, a significantly (p < 0.05) higher rate, 41.2% (21/51), of the novel deletions in the group of patients defined as N1-2 in comparison with 21.8% (12/55), in the group defined as N0. However, this result is not consistent with good statistical power which has a value around 0.6. There were no associations between the novel deletions and other clinical characteristics and no associations in the normal tissue (data not shown).

Observed novel mtDNA single nucleotide variants

Fifteen novel mtDNA single nucleotide variants were identified in the region sequenced and resident in the novel deletions reported here (Table 5). These were not linked to any clinical parameter available in this study (data not shown).
Table 5

Novel mtDNA single nucleotide variants detected in breast cancer and normal tissue

Sample no.

Tissue

Variant

10

Cancer

T13543A

19

Normal

T13386A

20

Normal

A13395G

24

Normal

G13414A

43

Normal

T13460C

52

Normal

G8790C

59

Normal

C8349T

61

Cancer

C8472A, A13519C

68

Cancer

A13395G

77

Cancer

C8270T, C13503T

86

Cancer

G13480T, T8317G

104

Cancer

T13488C

Discussion

The mitochondrial 4977 bp deletion has been found in tissues from several tumor types and adjacent normal tissues (Penta et al. 2001; Chen et al. 2011; Ye et al. 2008; Abnet et al. 2004; Dai et al. 2006). Recently, reduced mitochondrial mutagenesis in colorectal cancer has been shown, as well as a higher frequency of mtDNA mutagenesis, which may prevent colorectal cancer (Ericson et al. 2012). In the present study, the mtDNA 4977 bp deletion was found at a significantly higher frequency in normal tissue in comparison with paired cancer tissue in Vietnamese BC patients. We also observed a pervading heteroplasmy in the tissues. Our results are consistent with a previous study showing decreased proportions of the mtDNA 4977 bp deletion in various cancer types compared with adjacent normal tissue, such as breast (Ye et al. 2008), lung (Dai et al. 2006), gastric (Wu et al. 2005) and colorectal cancer (Dimberg et al. 2014). One explanation of this phenomenon might be a dilution of the mtDNA 4977 bp deletion in tumor tissue as a result of clonal expansion during cancer progression or that cells harbouring this deletion are eliminated by apoptosis (Wu et al. 2005). Moreover, the mtDNA 4977 bp deletion might confer a metabolic disadvantage to proliferating cells and thus is selected out in the highly proliferative tumor tissue (Wu et al. 2005).

Testing the tumor for hormonal receptors is a standard part of a BC diagnosis. In general BC with positive hormonal receptor status tends to be more aggressive and fast growing. Moreover, the receptor status predicts the treatment response and thus will influence the treatment regimen (Goldhirsch et al. 2009). In the present study, we found that the incidence of the 4977 bp deletion in BC tissue is significantly higher in the patients with ER positive as compared with ER negative patients. It has been reported that p53 plays a role in the maintenance of mtDNA integrity by controlling replication and repair through interaction with DNA pol gamma (Achanta et al. 2005). A study demonstrated that ER binds to p53 on the p53 target gene and represses p53 mediated transcriptional activation (Konduri et al. 2010) and may thus explain that 4977 bp deletion seems to be more prevalent among ER positive patients.

In addition to the 4977 bp deletion, we discovered novel large scale deletions, 36 in cancerous and 30 in normal tissue. Moreover, 15 novel mtDNA single nucleotide variants were identified within the region sequenced and resident in the novel deletions reported here.

Interestingly, we observed, in cancerous tissue, a significantly higher incidence of the novel deletions in the group of patients with lymph node metastasis in comparison with the patients with no lymph node metastasis. However, this result is preliminary because of insufficient number of patients. It is possible that our novel deletions are involved in the mediation of tumor progression. However, our finding does not provide answers as to whether mtDNA alterations are contributing factors to carcinogenesis or whether they simply arise as part of secondary effects in cancer progression. Whether our detected novel deletions have an impact on cancer development or not requires further investigation. Studies have shown that a reduced mtDNA content is associated with higher histological grade in BC (Yadav & Chandra 2013) while other studies failed to demonstrate any correlation with tumor grade or metastasis (Yadav & Chandra 2013; Mambo et al. 2005). In the future, it would be of interest to investigate this type of correlation in our group with increased number of patients.

To our knowledge, this is the first time that mtDNA alteration in BC tissue and paired normal tissue has been analyzed in Vietnamese patients. We have focused on identification of the 4977 bp deletion but also on characterization of novel mutations. The results about the novel mutations must be confirmed by expanding the investigation. Studies using increased sample size are required to determine the clinicopathologic role of the sequence variation of mtDNA in BC. Our finding may provide complementary information in additional studies to define the importance of the mtDNA deletions found in prediction of clinical outcome including metastasis, recurrence and survival of patients with BC.

Notes

Declarations

Acknowledgements

This work was supported by grants from Futurum the Academy of Healthcare, County Council of Jönköping, Sweden, the Foundation of Clinical Cancer Research, Jönköping Sweden and the University College of Health Sciences, Jönköping Sweden. This work was also financially supported by KC.04.10/11-15 project of Ministry of Science and Technology, Vietnam.

Authors’ Affiliations

(1)
Department of Natural Science and Biomedicine, University College of Health Sciences
(2)
Key Laboratory of Enzyme and Protein Technology, Department of Biology, College of Science, Vietnam National University
(3)
Departments of Clinical Microbiology, Ryhov County Hospital
(4)
Departments of Laboratory Services, Ryhov County Hospital

References

  1. Abnet CC, Huppi K, Carrera A, Armistead D, McKenney K, Hu N, Tang ZZ, Taylor PR, Dawsey SM (2004) Control region mutations and the common deletion are frequent in the mitochondrial DNA of the patients with esophageal squamous cell carcinoma. BMC Cancer 40:1–8Google Scholar
  2. Achanta G, Sasaki R, Feng L, Carew JS, Lu W, Pelicano H, Keating MJ, Huang P (2005) Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J 24:3482–3492View ArticleGoogle Scholar
  3. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403–410View ArticleGoogle Scholar
  4. Anh PT, Duc NB (2002) The situation with cancer control in Vietnam. Jpn J Clin Oncol 57:S92–S97View ArticleGoogle Scholar
  5. Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA (2014) Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers 2014:e513158View ArticleGoogle Scholar
  6. Birch-Machin MA (2006) The role of mitochondria in ageing and carcinogenesis. Clin Exp Dermatol 31:548–552View ArticleGoogle Scholar
  7. Chen T, He J, Shen L, Fang H, Nie H, Jin T, Wei X, Xin Y, Jiang Y, Li H, Chen G, Lu J, Bai Y (2011) The mitochondrial DNA 4,977-bp deletion and its implication in copy number alteration in colorectal cancer. BMC Med Genet 12:1–9Google Scholar
  8. Dai JG, Xiao YB, Min JX, Zhang GQ, Yao K, Zhou RJ (2006) Mitochondrial DNA 4977 bp deletion mutations in lung carcinoma. Indian J Cancer 43:20–25View ArticleGoogle Scholar
  9. Dani SU, Dani MA, Simpson AJ (2003) The common mitochondrial DNA deletion ΔmtDNA (4977): sheding new light to the concept of a tumor suppressor mutation. Med Hypotheses 61:60–63View ArticleGoogle Scholar
  10. Dimberg J, Hong TT, Skarstedt M, Löfgren S, Zar N, Matussek A (2014) Novel and differential accumulation of mitochondrial DNA deletions in Swedish and Vietnamese patients with colorectal cancer. Anticancer Res 34:147–152Google Scholar
  11. Ericson NG, Kulawiec M, Vermulst M, Sheahan K, O’Sullivan J, Salk JJ, Bielas JH (2012) Decreased mitochondrial DNA mutagenesis in human colorectal cancer. PloS Genet 8:e1002689View ArticleGoogle Scholar
  12. Eshaghian A, Vleugels RA, Canter JA, McDonald MA, Stasko T, Sligh JE (2006) Mitochondrial DNA deletions serve as biomarkers of aging in the skin but are typically absent in nonmelanoma skin cancers. J Invest Dermatol 126:336–344View ArticleGoogle Scholar
  13. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen international expert consensus on the primarytherapy of early breast cancer 2009. Ann Oncol 20:1319–1329View ArticleGoogle Scholar
  14. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90View ArticleGoogle Scholar
  15. Konduri SD, Medisetty R, Liu W, Kaipparettu BA, Srivastava P, Brauch H, Fritz P, Swetzig WM, Gardner AE, Khan SA, Das GM (2010) Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci USA 107:15081–15086View ArticleGoogle Scholar
  16. Larman TC, DePalma SR, Hadjipanayis AG, Cancer Genome Atlas Research Network, Protopopov A, Zhang J, Gabriel SB, Chin L, Seidman CE, Kucherlapati R, Seidman JG (2012) Spectrum of somatic mitochondrial mutations in five cancers. Proc Natl Acad Sci USA 109:14087–14097View ArticleGoogle Scholar
  17. Le GM, Gomez SL, Clarke C, Glaser SL, West DW (2002) Cancer incidence patterns among Vietnamese in the United States and Hanoi. Int J Cancer 102:412–417View ArticleGoogle Scholar
  18. Mambo E, Chatterjee A, Xing M, Tallini G, Haugen BR, Yeung S-C J, Sukumar S, Sidransky D (2005) Tumor-specific changes in mtDNA content in human cancer. Int J Cancer 116:920–924View ArticleGoogle Scholar
  19. McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer- Epidemiology, risk factors and genetics. BMJ 321:624–628View ArticleGoogle Scholar
  20. MITOMAP (2013). http://www.mitomap.org/MITOMAP (last accessed June 30, 2013)
  21. Penta JS, Johmson FM, Wachsman JT, Copeland WC (2001) Mitochondrial DNA in human malignancy. Mutat Res 488:119–133View ArticleGoogle Scholar
  22. Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117:3155–3163View ArticleGoogle Scholar
  23. Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, Domchek SM, Hartmann LC, Holland R, Winchester DJ (2008) Proceedings of the international consensus conference on breast cancer risk, genetics & risk management, April 2007. Cancer 113:2627–2637View ArticleGoogle Scholar
  24. Wu CW, Yin PH, Hung WY, Li AF, Li SH, Chi CW, Wei YH, Lee HC (2005) Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer 44:19–28View ArticleGoogle Scholar
  25. Yadav N, Chandra D (2013) Mitochondrial DNA mutations and breast tumorigenesis. Biochim Biophys Acta 1836:336–344Google Scholar
  26. Ye C, Shu XO, Wen W, Pierce L, Courtney R, Gao YT, Zheng W, Cai Q (2008) Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign diseases. Breast Cancer Res 108:427–434View ArticleGoogle Scholar

Copyright

© Dimberg et al.; licensee Springer. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.